Company: ARTL
Filing Date: 2025-10-01
Form Type: 424B5
Source: 0001640334-25-001763
Chunk: 11

Company: ARTELO BIOSCIENCES, INC.
Filing Date: 2025-10-01
Form: 424B5
Chunk 11
---
 | Development Phase | Estimated Global Market Size                                                                                                                                 |
| ART27.13 – Synthetic Dual Cannabinoid GPCR Agonist | Cancer-related anorexia                                                                       | Clinical          | Cancer anorexia cachexia syndrome: >$3 billion                                                                                                               |
| ART26.12 – FABP5 inhibitor                         | CIPN, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders | Clinical          | CIPN: >$2 billion Prostate cancer: approximately $13 billion Breast cancer: approximately $33 billion Psoriasis: $31 billion PTSD: approximately $13 billion |
| ART12.11 – Synthetic CBD Cocrystal                 | Anxiety, depression, PTSD, and other potential indications                                    | Pre-clinical      | Anxiety disorders: >$13 billion PTSD: approximately $13 billion                                                                                              |

| S-2 |

| S-3 |

| Recent Developments   On July 18, 2025, we entered into an At-The-Market Offering Agreement (the “Sales Agreement”) with R. F. Lafferty & Co., Inc. (“Lafferty”) under which we may offer and sell up to $6.5 million of shares of our common stock from time to time through an “at the market” offering program under which Lafferty will act as sales agent. Under the Sales Agreement, we will set the parameters for the sale of shares, including the number or dollar amount of shares to be issued, the time period during which sales are requested to be made, limitations on the number or dollar amount of shares that may be sold in any one trading day and any minimum price below which sales may not be made. Subject to the terms and conditions of the Sales Agreement, Lafferty may sell the shares by methods deemed to be an “at the market” offering as defined in Rule 415 promulgated under the Securities Act of 1933, as amended. We have no obligation to sell any shares under the Sales Agreement and may at any time suspend solicitation and offers under the Sales Agreement. The shares will be issued pursuant to our shelf registration statement on Form S-3, including the prospectus supplement contained therein, which was declared effective by the SEC on July 14, 2023. As of September 30, 2025, 50,858 shares of common stock have been sold under the ATM for net proceeds of $451,526.95. On September 30, 2025, we filed a prospectus